CTIM-76

May 06, 2026 — Context Therapeutics Inc. (Nasdaq: CNTX) reported first-quarter 2026 financial results and pipeline updates for its T cell engaging (TCE) bispecific antibody programs in solid tumors. The company expects Phase 1a interim data from CTIM-76 (CLDN6 x CD3) in June 2026, including preliminary safety, efficacy, and correlative results, and Phase 1a data from CT-95 (MSLN x CD3) in September 2026. Context also anticipates initiating a Phase 1 first-in-human study of CT-202 (Nectin-4 x CD3) in Q3 2026; in April 2026 it received Australian HREC approval and TGA CTN acknowledgement, and presented CT-202 preclinical data at AACR 2026. The FDA granted Fast Track Designation to CTIM-76 for platinum-resistant ovarian cancer (post–standard of care). Financially, cash and cash equivalents were $54.5M as of March 31, 2026 (vs. $66.0M at Dec. 31, 2025), expected to fund operations into mid-2027. Q1 2026 net loss was $8.7M (vs. $4.6M in Q1 2025), with R&D expenses rising to $7.0M.